MYGN - Myriad Genetics - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US62855J1043

Genetic Tests, Cancer Diagnostics, Precision Medicine

Myriad Genetics, Inc. is a pioneering genetic testing and precision medicine company that develops and commercializes innovative genetic tests to improve healthcare outcomes globally. With a strong presence in the United States and internationally, the company focuses on oncology, women's health, and pharmacogenomics.

The company's portfolio of molecular diagnostic tests includes the MyRisk Hereditary Cancer Test, a DNA sequencing test that assesses the risk of hereditary cancers. Additionally, Myriad offers the BRACAnalysis CDx Germline Companion Diagnostic Test, which helps determine therapy for patients with metastatic breast, ovarian, pancreatic, and prostate cancer who have deleterious or suspected deleterious germline BRCA variants.

Myriad's MyChoice CDx Companion Diagnostic Test is a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also provides the Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis that assesses the aggressiveness of prostate cancer. Furthermore, Myriad offers the EndoPredict Breast Cancer Prognostic Test, an RNA expression test that evaluates the aggressiveness of breast cancer.

The company's Precise Tumor solution enables precision oncology, while its Prequel Prenatal Screen is a non-invasive prenatal screening test that detects severe chromosomal disorders in a fetus using maternal blood. Myriad also offers the Foresight Carrier Screen, a prenatal test that assesses the risk of passing on recessive genetic conditions to offspring. The SneakPeek test predicts the gender of a fetus through a non-invasive blood test.

Moreover, Myriad's GeneSight Psychotropic Mental Health Medication Test is a DNA genotyping test that aids in psychotropic drug selection for patients with depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. The company has strategic collaborations with prominent organizations, including Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health.

Myriad Genetics, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah. With a strong commitment to advancing genetic testing and precision medicine, the company continues to innovate and improve healthcare outcomes worldwide. You can learn more about Myriad Genetics, Inc. at https://www.myriad.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for MYGN - Myriad Genetics  - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for MYGN - Myriad Genetics  - Stock Price & Dividends

MYGN Stock Overview

Market Cap in USD 2,258m
Sector Healthcare
Industry Diagnostics & Research
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 1995-10-05

MYGN Stock Ratings

Growth 5y 4.99
Fundamental -50.7
Dividend -
Rel. Performance vs Sector 1.68
Analysts 3.42/5
Fair Price Momentum 23.88 USD
Fair Price DCF -

MYGN Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 1.0%

MYGN Growth Ratios

Growth 12m 17.42%
Growth Correlation 12m 48%
Growth Correlation 3m 51%
CAGR 5y 0.27%
CAGR/Mean DD 5y 0.01
Sharpe Ratio 12m 0.24
Alpha vs SP500 12m -15.34
Beta vs SP500 5y weekly 1.30
ValueRay RSI 92.43
Volatility GJR Garch 1y 40.73%
Price / SMA 50 11.95%
Price / SMA 200 29.64%
Current Volume 843.8k
Average Volume 20d 853.9k

External Links for MYGN Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of MYGN stocks?
As of July 13, 2024, the stock is trading at USD 26.42 with a total of 843,813 shares traded.
Over the past week, the price has changed by +6.10%, over one month by +12.14%, over three months by +35.14% and over the past year by +16.75%.
What are the forecast for MYGN stock price target?
According to ValueRays Forecast Model, MYGN Myriad Genetics will be worth about 26.8 in July 2025. The stock is currently trading at 26.42. This means that the stock has a potential upside of +1.32%.
Issuer Forecast Upside
Wallstreet Target Price 25.2 -4.73
Analysts Target Price 20.7 -21.6
ValueRay Target Price 26.8 1.32